Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.150
-0.010 (-0.46%)
At close: Nov 4, 2024, 4:00 PM
2.100
-0.050 (-2.33%)
After-hours: Nov 4, 2024, 7:49 PM EST
Can-Fite BioPharma Employees
Can-Fite BioPharma had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$83,375
Profits / Employee
-$921,375
Market Cap
15.81M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
China Jo-Jo Drugstores | 1,003 |
T2 Biosystems | 113 |
Cumberland Pharmaceuticals | 91 |
Calidi Biotherapeutics | 41 |
Nephros | 31 |
Microbot Medical | 22 |
Traws Pharma | 18 |
Talphera | 15 |
CANF News
- 18 hours ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 17 days ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 26 days ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire
- 2 months ago - Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies - GlobeNewsWire
- 3 months ago - OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 3 months ago - Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - Can-Fite Provides Namodenoson Patent Update - GlobeNewsWire